Evidence map›Paper›PMID 26830359›Full record

ArticleCombinatorial chemistry & high throughput screening2016

High Throughput Screening for Colorectal Cancer Specific Compounds.

Jingping Xie, Chunxia Wang, John C Gore

Abstract read
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jingping XieVUIIS, Vanderbilt University, Nashville, TN 37232, USA. Jingping.Xie@vanderbilt.edu.
Chunxia Wang
John C GoreVUIIS, Vanderbilt University, Nashville, TN 37232, USA. John.Gore@vanderbilt.edu.
Nanfang Hospital · CNVanderbilt University · US

Funding

Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
South-Eastern Center for Imaging Animal Models of CancerU24CA126588 · NCI · VANDERBILT UNIVERSITY · PI GORE, JOHN C · 2007 to 2011
$2.1M
NCI NIH HHS 1P50CA128323NCI NIH HHS P50 CA128323NCI NIH HHS U24 CA126588NCI NIH HHS U24CA126588
6 · The paper itself

Abstract

The development of new anti-cancer therapeutic agents is necessary to improve antitumor efficacy and reduce toxicities. Here we report using a systematic anticancer drug screening approach we developed previously, to concurrently screen colon and glioma cancer cell lines for 2000 compounds with known bioactivity and 1920 compounds with unknown activity. The hits specific to each tumor cell line were then selected, and further tested with the same cells transfected with EGFP (Enhanced Green Fluorescent Protein) alone. By comparing the percentage of signal reduction from the same cells transfected with the sensor-conjugated reporter system; hits preferably causing apoptosis were identified. Among the known lead compounds, many cardiac glycosides used as cardiotonic drugs were found to effectively and specifically kill colon cancer cells, while statins (hypolipidemic agents) used as cholesterol lowering drugs were relatively more effective in killing glioma cells.

Indexed as

Drug Screening Assays, AntitumorHigh-Throughput Screening AssaysAntineoplastic AgentsApoptosisCardiac GlycosidesCardiotonic AgentsCell Line, TumorCell ProliferationColorectal NeoplasmsDose-Response Relationship, DrugGliomaHumansHypolipidemic AgentsStructure-Activity RelationshipAntineoplastic AgentsCardiac GlycosidesCardiotonic AgentsHypolipidemic Agents

Identifiers

PMID26830359
PMCPMC6947929
OpenAlexW2317187503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.